|
|
Article: Archemix Names Dr. Errol De Souza President and CEO; To Lead Development of Aptamers as New Class of Therapeutics.
- Article from:
- PR Newswire
- Article date:
- April 8, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass. -- CAMBRIDGE, Mass., April 8 /PRNewswire/ -- Archemix Corp., the biopharmaceutical company developing aptamer therapeutics, announced today the appointment of Dr. Errol De Souza as President and Chief Executive Officer.
Dr. De Souza, most recently President and CEO of Synaptic Pharmaceutical Corporation, has significant experience in drug discovery and product development, within both biotechnology and large pharmaceutical settings.
Dr. Martin Stanton, Co-founder and Executive Vice President says, "Archemix has established aptamer technology as the basis for a new class of directed therapeutics. Errol De Souza, with his extensive ...